GV1001 is based on a European patent developed by Gustav Gaudernack's group at the Section of immunotherapy at the Norwegian Radium Hospial, in cooperation with Norsk Hydro.
Jakob Schmidt, CEO in Pharmexa says:
"The Innovation Award first and foremost recognizes the great efforts Radiumhospitalet (Norway), Ullevål Universitetssykehus (Norway) and GemVax's founders with good support from Norges Forskningsråd have put into developing GV1001 to a stage where we can see the outlines of a new ground-breaking drug."
In connection with the Innovation Award chairman of DnB NOR Olav Hytta says:
"The work with the vaccine is a good example of knowledge based business development in Denmark and Norway. GemVax has developed the technology whereas Pharmexa has the clinical, regulatory and manufacturing competences necessary for the further commercialization of the product. GV1001 has the potential to become a universal cancer vaccine, and if successful it could result in major international benefits for individuals, the society and the company."
GemVax AS was sold to Pharmexa in April 2005.
Read about it here: GemVax AS sold to Pharmexa
Pharmexa A/S is a leading company in the field of active immunotherapy for the treatment of serious chronic diseases. Pharmexa's proprietary technology platforms are broadly applicable, but the company has focused its resources on cancer and chronic inflammatory diseases, with research and development programs targeted towards various cancer forms, rheumatoid arthritis, bone degeneration, Alzheimer's disease and others. Its leading programs are GV1001, a peptide vaccine about to enter phase III trials in pancreatic cancer and HER-2 AutoVacä Protein, a recombinant protein vaccine in phase II against breast cancer. Collaborative agreements include Schering-Plough, H. Lundbeck and Bavarian Nordic.
Home page: www.pharmexa.com